MedTrace Logo

Rifaximin Modify the Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD)

NCT02884037 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2017-08-11

No results posted yet for this study

Summary

In this multicentric, double-blind, randomized,placebo-controlled study, the investigators hypothesized that rifaximin might act on Gram-negative bacteria and intestinal bacterial overgrowth(IBO) thereby inhibiting lipopolysaccharides(LPS)-mediated proinflammatory cytokine production. This work evaluates the efficacy of 6 months administration of rifaximin in NAFLD patients.

Conditions

  • Non-alcoholic Fatty Liver Disease

Interventions

DRUG

Rifaximin group 1

Rifaximin: 1100mg/day, 550 mg tablets 1 × 2 before meals

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2015-05-31
Completion
2016-10-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02884037 on ClinicalTrials.gov